HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Naratriptan
Naratriptan · Naratriptan1 · Naratriptane · Naratriptan(Amerge) · Naratriptan, 10 mM in DMSO · AMERGE · NARAMIG · GR-85548A
Identifikatoren & physikalische Daten
| CAS No. | 121679-13-8 |
|---|---|
| Summenformel | C17H25N3O2S |
| Durchschnittliche Molmasse | 335,5 g/mol |
| Monoisotopische Masse | 335,16674804 g/mol |
| SMILES | CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1 |
| InChIKey | AMKVXSZCKVJAGH-UHFFFAOYSA-N |
| PubChem CID | 4440 |
| ChEMBL | CHEMBL1278 |
| ChEBI | CHEBI:7478 |
| EC No. | 601-800-8 |
| DTXSID | DTXSID7023354 |
Chemische & physikalische Eigenschaften
| XLogP | 2 |
|---|---|
| Polarare Oberfläche (TPSA) | 73,6 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 23 |
| Formalladung | 0 |
| Komplexität | 483 |
| Arzneimittel | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 1.6 |
| Löslichkeit | 1.14e-01 g/L |
| Human Drugs | Breast FeedingLactationMilk, HumanSerotonin Receptor AgonistsSerotonin 5-HT1 Receptor AgonistsTriptansVasoconstrictor AgentsPharmaceuticals |
| Schmelzpunkt | 246 °C (hydrochloride salt)170-171° |
| Physical Description | Solid |
| Collision Cross Section | 174.3 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| Siedepunkt | 541.3±60.0 °C(Predicted) |
| Dichte | 1.227±0.06 g/cm3(Predicted) |
| pKa (Säurekonstante) | 11.52±0.40(Predicted) |
Sicherheit & Vorschriften
| Treatment | There is no specific antidote to naratriptan. Standard supportive treatment should be applied as required. If the patient presents with chest pain or other symptoms consistent with angina pectoris, ECG monitoring should be performed for evidence of ischemia. (L1712) |
|---|---|
| Expositionspfade | Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack. |
| Toxizitätsübersicht | Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation(2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism. |
| Signs and Symptoms | Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)naratriptanDILI NegativeOralDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
Anwendungen & Verwendung
Verwenden
Naratriptan is a triptan drug that is used for the treatment of migraine headaches.